Central Trust Company’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $901K | Sell |
14,358
-775
| -5% | -$62K | 0.02% | 357 |
|
|
2025
Q4 | $1.44M | Sell |
15,133
-925
| -6% | -$90.7K | 0.03% | 288 |
|
|
2025
Q3 | $1.57M | Buy |
16,058
+1,962
| +14% | +$203K | 0.03% | 285 |
|
|
2025
Q2 | $1.51M | Buy |
14,096
+2,624
| +23% | +$266K | 0.03% | 284 |
|
|
2025
Q1 | $1.16M | Buy |
11,472
+5,976
| +109% | +$602K | 0.03% | 302 |
|
|
2024
Q4 | $491K | Sell |
5,496
-22
| -0.4% | -$1.94K | 0.01% | 416 |
|
|
2024
Q3 | $462K | Sell |
5,518
-549
| -9% | -$43.3K | 0.01% | 419 |
|
|
2024
Q2 | $467K | Sell |
6,067
-150
| -2% | -$11K | 0.01% | 415 |
|
|
2024
Q1 | $426K | Sell |
6,217
-265
| -4% | -$17K | 0.01% | 439 |
|
|
2023
Q4 | $375K | Sell |
6,482
-535
| -8% | -$28.6K | 0.01% | 443 |
|
|
2023
Q3 | $370K | Sell |
7,017
-1,680
| -19% | -$88.1K | 0.01% | 444 |
|
|
2023
Q2 | $470K | Sell |
8,697
-170
| -2% | -$8.88K | 0.01% | 420 |
|
|
2023
Q1 | $444K | Buy |
8,867
+125
| +1% | +$5.89K | 0.01% | 426 |
|
|
2022
Q4 | $404K | Sell |
8,742
-120
| -1% | -$5.2K | 0.01% | 422 |
|
|
2022
Q3 | $343K | Buy |
8,862
+310
| +4% | +$12.4K | 0.01% | 432 |
|
|
2022
Q2 | $319K | Buy |
8,552
+7,865
| +1,145% | +$320K | 0.01% | 448 |
|
|
2022
Q1 | $30K | Hold |
687
| – | – | ﹤0.01% | 886 |
|
|
2021
Q4 | $29K | Hold |
687
| – | – | ﹤0.01% | 887 |
|
|
2021
Q3 | $30K | Hold |
687
| – | – | ﹤0.01% | 844 |
|
|
2021
Q2 | $29K | Hold |
687
| – | – | ﹤0.01% | 812 |
|
|
2021
Q1 | $27K | Hold |
687
| – | – | ﹤0.01% | 782 |
|
|
2020
Q4 | $25K | Hold |
687
| – | – | ﹤0.01% | 765 |
|
|
2020
Q3 | $26K | Hold |
687
| – | – | ﹤0.01% | 729 |
|
|
2020
Q2 | $24K | Sell |
687
-600
| -47% | -$21.6K | ﹤0.01% | 715 |
|
|
2020
Q1 | $42K | Buy |
1,287
+500
| +64% | +$19.5K | ﹤0.01% | 636 |
|
|
2019
Q4 | $36K | Hold |
787
| – | – | ﹤0.01% | 728 |
|
|
2019
Q3 | $32K | Hold |
787
| – | – | ﹤0.01% | 714 |
|
|
2019
Q2 | $34K | Hold |
787
| – | – | ﹤0.01% | 711 |
|
|
2019
Q1 | $30K | Hold |
787
| – | – | ﹤0.01% | 709 |
|
|
2018
Q4 | $28K | Hold |
787
| – | – | ﹤0.01% | 725 |
|
|
2018
Q3 | $30K | Hold |
787
| – | – | ﹤0.01% | 760 |
|
|
2018
Q2 | $26K | Hold |
787
| – | – | ﹤0.01% | 773 |
|
|
2018
Q1 | $22K | Buy |
787
+687
| +687% | +$18.7K | ﹤0.01% | 811 |
|
|
2017
Q4 | $2K | Sell |
100
-1,245
| -93% | -$34.3K | ﹤0.01% | 1185 |
|
|
2017
Q3 | $39K | Buy |
1,345
+687
| +104% | +$19K | ﹤0.01% | 725 |
|
|
2017
Q2 | $18K | Buy |
658
+350
| +114% | +$9.29K | ﹤0.01% | 850 |
|
|
2017
Q1 | $8K | Hold |
308
| – | – | ﹤0.01% | 990 |
|
|
2016
Q4 | $7K | Hold |
308
| – | – | ﹤0.01% | 1037 |
|
|
2016
Q3 | $7K | Hold |
308
| – | – | ﹤0.01% | 987 |
|
|
2016
Q2 | $7K | Hold |
308
| – | – | ﹤0.01% | 1008 |
|
|
2016
Q1 | $6K | Buy |
+308
| New | +$5.41K | ﹤0.01% | 1001 |
|
Other funds holding BSX
VCM
VPM
Central Trust Company's BSX Position: Q1 2026 in Review
Central Trust Company reduced its Boston Scientific (BSX) stake by 5.1% in Q1 2026, selling an estimated $62K and leaving 14,358 shares worth $901K. The position accounts for 0.02% of the portfolio, ranked #357.
Central Trust Company first reported a position in BSX in Q1 2016 and has held it in 41 quarters since. The position peaked at $1.57M in Q3 2025. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.
- Central Trust Company held 14,358 shares of Boston Scientific worth $901K as of Q1 2026.
- Central Trust Company sold 775 Boston Scientific shares in Q1 2026, an estimated $62K.
- Boston Scientific made up 0.02% of Central Trust Company's portfolio in Q1 2026, its #357 holding.
- Central Trust Company first reported a position in Boston Scientific in Q1 2016 and has held it in 41 quarters since.
- Central Trust Company's Boston Scientific position peaked at $1.57M in Q3 2025.
- 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.
Based on Central Trust Company's 13F filing for Q1 2026, filed 17 Apr 2026.